CoChat

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Open access
Ivanova, Elena, Kuraguchi, Mari, Xu, Man, Portell, Andrew J., Taus, Luke, Diala, Irmina, Lalani, Alshad S., Choi, Jihyun, Chambers, Emily S., Li, Shuai, Liu, Shengwu, Chen, Ting, Barbie, Thanh U., Oxnard, Geoffrey R., Haworth, Jacob J., Wong, Kwok-Kin, Dahlberg, Suzanne E., Aref, Amir A., Barbie, David A., Bahcall, Magda, Paweletz, Cloud P., Jänne, Pasi A. · 2020 · Clinical Cancer Research
Cited by 43

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Purpose: Evaluating drug responses using primary patient-derived cells ex vivo represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in HER2 mutant non–small cell lung cancer (NSCLC) patient xenograft-derived organotypic spheroids (XDOTS) using a short-term ex vivo system. Experimental Design: We generated two HER2-mutant NSCLC PDX models [DFCI359 (HER2 exon19 755_757LREdelinsRP) and DFCI315 (HER2 exon20 V777_G778insGSP)] and used the PDX tumors to generate XDOTS. Tumor spheroids were grown in a microfluidic device and treated ex vivo with neratinib-based drug combinations. Live/dead quantification was performed by dual-labeling deconvolution fluorescence microscopy. The most efficacious ex vivo combination was subsequently validated in vivo using the DFCI359 and DFCI315 PDXs and a HER2YVMA genetically engineered mouse model. Results: Both neratinib and afatinib, but not gefitinib, induced cell death in DFCI359 XDOTS. The combinations of neratinib/trastuzumab and neratinib/temsirolimus enhanced the therapeutic benefit of neratinib alone in DFCI315 and DFCI359. The combination of neratinib and trastuzumab in vivo was more effective compared with single-agent neratinib or trastuzumab and was associated with more robust inhibition of HER2 and downstream signaling. Conclusions: The XDOTS platform can be used to evaluate therapies and therapeutic combinations ex vivo using PDX tumors. This approach may accelerate the identification and clinical development of therapies for targets with no or few existing models and/or therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1844

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 43

Metadata

Authors
Ivanova, E., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., Liu, S., Chen, T., Barbie, T. U., Oxnard, G. R., Haworth, J. J., Wong, K.-K., Dahlberg, S. E., Aref, A. A., Barbie, D. A., Bahcall, M., Paweletz, C. P., & Jänne, P. A.
Venue
Clinical Cancer Research
Published
2020-05-15
Volume
26
Issue
10
Pages
2393-2403
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3005121071
Cited by
43
References
20
FWCI
3.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1844
The paper
Ivanova, E., Kuraguchi, M., Xu, M., Portell, A. J., Taus, L., Diala, I., Lalani, A. S., Choi, J., Chambers, E. S., Li, S., Liu, S., Chen, T., Barbie, T. U., Oxnard, G. R., Haworth, J. J., Wong, K.-K., Dahlberg, S. E., Aref, A. A., Barbie, D. A., . . . Jänne, P. A. (2020). Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.